Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

以兹提米比 辛伐他汀 医学 心肌梗塞 他汀类 内科学 不稳定型心绞痛 安慰剂 胆固醇 临床终点 随机化 联合疗法 胃肠病学 急性冠脉综合征 泌尿科 心脏病学 随机对照试验 替代医学 病理
作者
Christopher P Cannon,Michael A. Blazing,Robert P. Giugliano,Amy McCagg,Jennifer A. White,Pierre Théroux,Harald Darius,Basil S. Lewis,Ton Oude Ophuis,J. Wouter Jukema,Gaetano Maria De Ferrari,Witold Rużyłło,P Lucca,KyungAh Im,Erin A. Bohula,Craig J. Reist,Stephen D. Wiviott,Andrew M. Tershakovec,Thomas A. Musliner,Eugene Braunwald,Robert M. Califf
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:372 (25): 2387-2397 被引量:3493
标识
DOI:10.1056/nejmoa1410489
摘要

Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke. The median follow-up was 6 years.The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P=0.016). Rates of prespecified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups.When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit. (Funded by Merck; IMPROVE-IT ClinicalTrials.gov number, NCT00202878.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善学以致用应助tk采纳,获得10
刚刚
1秒前
qqqq完成签到,获得积分10
1秒前
2秒前
zxt完成签到 ,获得积分10
3秒前
MY发布了新的文献求助10
3秒前
思源应助失眠的雁芙采纳,获得10
4秒前
6秒前
7秒前
dong应助wyf采纳,获得10
7秒前
9秒前
逸鑫林完成签到 ,获得积分10
9秒前
9秒前
11秒前
14秒前
唐禹嘉完成签到 ,获得积分10
14秒前
无算浮白发布了新的文献求助10
14秒前
14秒前
Lyuhng+1发布了新的文献求助10
15秒前
17秒前
18秒前
Hello应助errui采纳,获得10
19秒前
葡萄完成签到,获得积分10
20秒前
zzz发布了新的文献求助10
21秒前
Leukocyte完成签到 ,获得积分10
21秒前
MaFY完成签到,获得积分10
23秒前
烟花应助zzk采纳,获得10
23秒前
小高宽度发布了新的文献求助10
24秒前
24秒前
25秒前
FashionBoy应助澡雪采纳,获得10
25秒前
22222发布了新的文献求助10
26秒前
科研通AI5应助147采纳,获得10
26秒前
26秒前
萝卜丁完成签到 ,获得积分0
27秒前
27秒前
27秒前
27秒前
852应助ssx采纳,获得20
29秒前
小金刀完成签到,获得积分10
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976177
求助须知:如何正确求助?哪些是违规求助? 3520366
关于积分的说明 11202970
捐赠科研通 3256899
什么是DOI,文献DOI怎么找? 1798535
邀请新用户注册赠送积分活动 877725
科研通“疑难数据库(出版商)”最低求助积分说明 806516